Clinical Trial Update: Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of lenalidomide (Revlimid) with fludarabine-rituximab in patients with chronic lymphocytic leukemia and small lymphocytic leukem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Leukemia

Drugs mentioned

• Fludarabine (Fludarabine)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 1 | Status: TERMINATED